SANUWAVE Health, Inc. Q2 FY2024 earnings call

• Q2 2024 revenue was $7.2 million, up 53% y-o-y, with gross margin at 73%. Operating and adjusted EBITDA were positive despite additional costs. - Increased quarterly revenue growth guidance: Q1/Q2 from 45%-55% to 65%-75% y-o-y for Q3. - Added to sales force and commercial operations, ramped up manufacturing capacity. - UltraMIST systems sold up 47% y-o-y, ending Q2 with 788 active systems. Applicator revenue up 67% y-o-y. - Terminated merger with SEPA due to no path to National Securities Exchange listing; working to simplify capital structure, including reverse stock split and note warrant exchange.

In Q2 2024, SANUWAVE achieved record quarterly revenue of $7.2 million, a 53% increase year-on-year. The UltraMIST product line saw systems sold up 47% from Q2 2023, with revenue from this line increasing 62% year-on-year. Consumable applicators revenue grew 67% year-on-year and 15% sequentially from Q1 2024. Applicator revenues made up roughly 65% of total revenues in Q2, with the aim to reduce this to the 55% range as the company focuses on selling more systems and growing the user base.

• Raised Q3 2024 revenue growth guidance to 65%-75% versus prior year. - Already sold more systems in Q3 2024 than in all of Q3 last year. - Q1 and Q2 revenue growth guidance increased from 45%-55% to 65%-75%.

• Termination of merger with SEPA as there was no path to National Securities Exchange listing for the post-merger entity. - Reverse splits have had a bad history in general, but in SANUWAVE's case, it's different as fundamentals are strong.

Q: Asked about actual numbers, customer acquisition, website optimization, and stock price.

A: Morgan Frank and Peter Sorensen responded on sales channels, acquisition costs, cap structure, and future outreach towards The Street once cap structure is simplified to make the company's value more visible